Recent articles for private investors with a focus on dividend announcements
26 Feb 2013
26 Feb 2013
26 Feb 2013
05 Mar 2013
26 Feb 2013
26 Feb 2013
25 Feb 2013
25 Feb 2013
25 Feb 2013
25 Feb 2013
25 Feb 2013
25 Feb 2013
25 Feb 2013
25 Feb 2013
25 Feb 2013
25 Feb 2013
22 Feb 2013
21 Feb 2013
21 Feb 2013
21 Feb 2013
21 Feb 2013
21 Feb 2013
21 Feb 2013
21 Feb 2013
21 Feb 2013
21 Feb 2013
21 Feb 2013
20 Feb 2013
20 Feb 2013
20 Feb 2013
20 Feb 2013
20 Feb 2013
20 Feb 2013
20 Feb 2013
21 Feb 2013
21 Feb 2013
19 Feb 2013
19 Feb 2013
19 Feb 2013
19 Feb 2013
19 Feb 2013
20 Feb 2013
19 Feb 2013
15 Feb 2013
15 Feb 2013
14 Feb 2013
14 Feb 2013
Shire Increases 2012 final dividend by 18%
Financial Highlights Full Year 2012Product sales $4,407 million +12%Product sales excluding ADDERALL XR $3,978 million +16%Total revenues $4,681 million +10%Non GAAP operating income $1,474 million +9%US GAAP operating income $949 million -14%Non GAAP diluted earnings per ADS $6.10 +14%US GAAP diluted earnings per ADS $3.93 -13%Non GAAP cash generation $1,637 million +18%Non GAAP free cash flow $1,256 million +43%US GAAP net cash provided by operating activities $1,383 million +29%DIVIDENDIn respect of the six months ended December 31, 2012 the Board has resolved topay an interim dividend of 14.60 US cents per ordinary share (2011: 12.59 UScents per ordinary share).Dividend payments will be made in Pounds Sterling to ordinary shareholders andin US Dollars to holders of ADSs. A dividend of 9.39 pence per ordinary share(2011: 7.96 pence) and 43.80 US cents per ADS (2011: 37.77 US cents) will bepaid on April 9, 2013 to shareholders on the register as at the close ofbusiness on March 8, 2013.Together with the first interim payment of 2.73 US cents per ordinary share(2011: 2.48 US cents per ordinary share), this represents total dividends for2012 of 17.33 US cents per ordinary share (2011: 15.07 US cents per ordinaryshare), an increase of 15% in US Dollar terms.Angus Russell, Chief Executive Officer, commented:"It's been another strong year for Shire with 12% growth in product sales and14% growth in Non GAAP earnings which have driven particularly strong cashgeneration. While delivering strong financial results, we continue to invest inour emerging late stage R&D pipeline.Our ADHD portfolio is performing very well in a growing global market and wesee further growth going forward. The positive opinion received from theEuropean regulators for ELVANSE is a significant milestone and we're nowpreparing for country launches in some of the largest markets in Europe. Allour rare disease treatments continue to grow and we saw particularly strongperformance from FIRAZYR in its first full year in the US market. We advancedour plans for developing our Regenerative Medicine business with theacquisition of VASCUGEL and the approval of DERMAGRAFT in Canada.Our late stage R&D pipeline now holds the prospect of future growth from LDX(the active ingredient in VYVANSE) in major depressive disorder, binge eatingdisorder and negative symptoms of schizophrenia. Our intrathecal programs arealso progressing well as we plan the next clinical trials for Hunter CNS andSanfilippo A and continue to enrol MLD patients into the ongoing Phase 1/2trial. A phase 2b study of SPD602, our iron chelating product, is underway andheadline results are expected later this year.We've completed a number of in-licensing deals and acquisitions in 2012,bringing us new technology platforms in rare diseases, hematology and a rangeof early stage and exciting differentiated treatments.We've put in place our leadership succession plan. Dr. Flemming Ørnskov joinedus at the beginning of January and is familiarising himself with the businessbefore he assumes the role of CEO at the end of April. His considerablepharmaceutical and international experience will benefit Shire going forward.Today we announce that Sylvie Gregoire, President of our HGT business, hasdecided to leave Shire at the end of March, after five years. We're gratefulfor her significant contributions to the growth of Shire through establishingHGT as a leader in rare diseases.Shire is in great shape, with the current business performing well, a promisingpipeline of new growth opportunities, and the strategy in place to deliver anexciting future. As we look forward to the year ahead, we expect our financialresults to show further growth in line with current consensus earningsexpectations for 2013(1)."
14 Feb 2013
14 Feb 2013
14 Feb 2013
